Compact CLIA Analyzer Supports Fast Routine IgE Testing

[admin]

Addressing the Need for Sensitive, Portable Allergy Diagnostics

Clinical departments handling allergy and immunology testing often face a common limitation: conventional ELISA-based in vitro assays may return negative results when specific IgE levels are low. This gap creates a demand for testing options that combine sensitivity, speed, and portability. Nanjing Poclight Biotechnology Co., Ltd, operating under the brand name Poclight, has positioned itself as a biotechnology company offering CLIA-based in vitro diagnostic assays paired with dry micro analyzer systems for allergy and immunology testing. The company’s IgE Assay in CLIA, used together with the C5000 Dry Micro System, illustrates how a compact chemiluminescence immunoassay analyzer can be integrated into routine IgE testing workflows.

How Chemiluminescence Immunoassay Technology Improves Detection

The IgE Assay in CLIA is built on a Chemiluminescence Immunoassay (CLIA) platform combined with a Dry Micro System that uses wash-free separation and does not rely on magnetic beads. This design choice directly addresses two operational concerns: reducing operating cost and reducing maintenance burden, since laboratories do not need to manage wash steps or bead-based separation processes.

From a sensitivity standpoint, the assay detects IgE as low as 0.1 IU/mL, which supports the identification of low-titer sensitization that may otherwise go undetected. According to the World Allergy Organization Journal (2020), in cases with low specific IgE levels, CLIA-based assays return more positive results than ELISA. This finding is directly relevant to the industry pain point that conventional ELISA-based in vitro assays may return negative results at low specific IgE levels, reinforcing why a CLIA-based approach is being positioned as a solution for clinical departments seeking a sensitive, rapid, and portable testing option for allergy diagnosis.

Quantitative Precision Across a Wide Linear Range

Beyond detecting the presence of IgE, the assay is designed to quantify it. The linear dynamic range of 0.1–2500 IU/mL allows clinicians to track changes in IgE levels after intervention, rather than relying solely on qualitative positive/negative reporting. The assay also reports a coefficient of variation of less than 3%, indicating consistency in repeated measurements. Together, these two technical characteristics—wide linear range and low variability—support the assay’s positioning as a quantitative chemiluminescence immunoassay for measuring total and specific IgE, intended for both allergy diagnosis and ongoing monitoring.

The product line also supports component allergen testing, referencing published positive predictive value (PPV) thresholds for specific allergens. For example, published data cite a specific IgE threshold of ≥5 U/mL for Peanut (Ara h2) with a PPV of 96%, and a threshold of ≥3.5 U/mL for Dust Mite (Der p1) with a PPV of 90%. Additional published thresholds cover allergens such as Cat (Fel d1), Birch Pollen (Bet v1), Grass Pollen (Phl p5), Dog (Can f1), Egg, Cow’s Milk, Fish, and Soy, each with its own PPV value. These reference points give clinicians an objective basis for allergy risk stratification rather than relying on qualitative impressions alone.

Compact Instrument Design Built for Routine Workflow

The C5000 Dry Micro System is the instrument platform that runs the IgE assay, and its specifications are oriented toward point-of-care and departmental use rather than centralized, high-volume laboratory settings alone. The system delivers an initial sample result in 3 minutes and operates across 7 channels simultaneously, supporting a throughput of 80 tests per hour. This combination of short turnaround and multi-channel operation is intended to support department workflow without requiring large batch processing.

Physically, the instrument weighs ≤8.5 kg, a specification described as enabling point-of-care use given its portable design. The system includes a touch screen for operation and supports LIS/HIS transmission, allowing results to be shared with laboratory and hospital information systems in real time. For reagent logistics, the platform is compatible with both lyophilized reagents, which can be stored and transported at room temperature, and liquid reagents, giving departments flexibility depending on their storage infrastructure.

Clinical Scenarios Where Rapid IgE Testing Matters

The knowledge base outlines several scenarios where the combination of sensitivity, quantitation, and speed is relevant. In Immunology, the assay helps confirm IgE-mediated allergies as distinct from non-IgE reactions such as eosinophilic esophagitis. In Emergency settings, rapid identification of anaphylaxis triggers is a stated use case, which aligns with the assay’s 3-minute initial result and portable form factor. In the Respiratory Department, the assay supports evaluation of allergic asthma exacerbations linked to aeroallergens such as pollen and dust mites. In Dermatology, it helps differentiate atopic dermatitis flares triggered by food versus environmental allergens.

The assay’s application coverage extends further to parasitic infections, where it can be combined with stool exams or serology, as well as immune-related disorders such as Hyper-IgE Syndrome (HIES) and Allergic Bronchopulmonary Aspergillosis (ABPA), skin diseases including Atopic Dermatitis (AD) and Bullous Pemphigoid, hematologic disorders such as IgE Myeloma and Hypereosinophilic Syndrome (HES), and drug hypersensitivity reactions, including IgE-mediated reactions to drugs such as penicillin and anticonvulsants.

Target patient populations described alongside these clinical scenarios include Pediatrics, Adults, and Pregnant Women. For pediatric patients, the described use case involves early detection of food allergies such as peanut, milk, and egg to guide weaning practices, along with monitoring the resolution of milk or egg allergies over time. For adults, the described use case is diagnosing late-onset food allergies, such as shellfish and tree nuts, along with occupational asthma. For pregnant women, the described application is risk stratification for offspring with familial atopy.

A Practical Fit for Departments Seeking Faster Allergy Testing

Taken together, the technical profile of the IgE Assay in CLIA running on the C5000 Dry Micro System reflects a deliberate combination of sensitivity (0.1 IU/mL detection limit), quantitation (0.1–2500 IU/mL linear range), speed (3-minute initial result, 80 tests/hour), and portability (≤8.5 kg, touch screen operation, LIS/HIS connectivity). For hospital clinical departments evaluating options for routine IgE testing—whether in immunology, emergency medicine, respiratory care, or dermatology—these documented specifications and the described wash-free, bead-free separation process illustrate how Poclight’s compact CLIA analyzer is designed to fit into everyday diagnostic workflows without adding operational complexity.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts